包装 | 价格(元) |
500 µg | 电议 |
1mg | 电议 |
5mg | 电议 |
Canonical SMILES | O=C(CCCCCCCCCCCCC)NCC(N[C@@H](CCCNC(N)=N)C(N[C@@H]([C@H](O)C)C(NCC(N[C@@H](CCCNC(N)=N)C(N[C@@H](CCCNC(N)=N)C(N[C@@H](CC(N)=O)C(N[C@@H](C)C(N[C@H](C(N)=O)[C@@H](C)CC)=O)=O)=O)=O)=O)=O)=O)=O.OC(C(F)(F)F)=O |
分子式 | C53H100N20O12·XCF3COOH |
分子量 | 1209.5 |
溶解度 | DMSO: 1 mg/ml,DMSO:PBS (pH 7.2) (1:3): 0.25 mg/ml |
储存条件 | -20°C |
General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while. |
Shipping Condition | Evaluation sample solution : ship with blue ice All other available size: ship with RT , or blue ice upon request |
产品描述 | PKI (14-22) amide (myristoylated) is a cell-permeable peptide inhibitor of protein kinase A (PKA).1,2,3It inhibits PKA activity in mouse brain or spinal cord lysates when used at a concentration of 75 µM.1PKI (14-22) amide (myristoylated) reduces IgG-dependent phagocytosis of heat-killedS. cerevisiaeby isolated human neutrophils in a concentration-dependent manner.2It inhibits the replication of several strains of Zika virus, including IbH 30656, MR766, H/FP/2013, and PRVABC59, in human umbilical vein endothelial cells (HUVECs; IC50s = 17.75, 22.29, 34.09, and 19.19 µM, respectively).3PKI (14-22) amide (myristoylated) (2.5 nmol, i.c.v.) increases latency to tail withdrawal in the tail-flick test in morphine-tolerant mice.1 1.Dalton, G.D., Smith, F.L., Smith, P.A., et al.Alterations in brain Protein Kinase A activity and reversal of morphine tolerance by two fragments of native Protein Kinase A inhibitor peptide (PKI)Neuropharmacology48(5)648-657(2005) 2.Ydrenius, L., Majeed, M., Rasmusson, B.J., et al.Activation of cAMP-dependent protein kinase is necessary for actin rearrangements in human neutrophils during phagocytosisJ. Leukoc. Biol.67(4)520-528(2000) 3.Cheng, F., da Silva, S.R., Huang, I.-C., et al.Suppression of Zika virus infection and replication in endothelial cells and astrocytes by PKA inhibitor PKI 14-22J. Virol.92(4)e02019-02017(2018) |